Acriptega Tablet

Acriptega Tablet contains Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate is an antiretroviral medication used in the management of HIV-1 infection. Consult your doctor if you are pregnant, breastfeeding, or have any health condition before starting treatment. Regular blood tests may be needed, and if you're HIV positive, avoid breastfeeding and sharing personal items; ask about safe sex practices to prevent HIV transmission.

1. What is Acriptega?Ingredients Acriptega includes 3 active ingredients: Dolutegravir, Lamivudine, Tenofovir with the following strengths: Dolutegravir: 50mg; Lamivudine: 300mg; Tenofovir disoproxil: 300mg. The active ingredient Lamivudine in Agriptera is rapidly absorbed after oral administration with a bioavailability of about 80-85%. Lamivudine is eliminated mainly unchanged by the kidneys and the half-life ranges from 5 to 7 hours. Tenofovir disoproxil fumarate is rapidly absorbed and then converted to Tenofovir. Bioavailability is approximately 25% when taken on an empty stomach, increasing with a high-fat meal. Tenofovir in Agriptera is eliminated mainly by the kidneys, both by glomerular filtration and by the renal tubular transport system with approximately 70-80% of the dose excreted unchanged in the urine. Dolutegravir for rapid absorption after oral administration, average Tmax about 2-3 hours. Food is the factor that increases the extent but slows down the rate of absorption of Dolutegravir. Therefore, Agriptera is recommended to be taken with food in integrase-resistant HIV patients. The drug is metabolised via glucuronide binding and to a small extent via the CYP3A4 system. Unchanged form Dolutegravir is eliminated by the kidneys very little ( 1% of the dose), most of which (about 53% of the oral dose) is eliminated unchanged in the faeces. 2. Uses of AcriptegaAcriptega is indicated in the following cases: Treatment of HIV-1 infection in adults and adolescents (aged 12 years and older and weighing more than 40 kg) with viral suppression to HIV1 RNA levels 50 copies/ml according to current antiretroviral combination regimen for at least 3 months; The patient had no virological failure on previous antiretroviral regimens. Lamivudine is a dideoxynucleoside analogue and Tenofovir disoproxil fumarate is converted into Tenofovir, a Nucleoside Monophosphate analogue. Lamivudine and Tenofovir are phosphorylated via cellular enzymes to form Lamivudine triphosphate and tenofovir diphosphate. These two active ingredients competitively inhibit HIV-1 reverse transcriptase, thereby ending DNA. Therefore, the 2 active ingredients in Agriptera have anti-HIV1 and HIV2 effects, in addition to the ability to fight hepatitis B virus. The other active ingredient in Agriptera is Dolutegravir, which inhibits HIV integrase through binding to the Integrase active site and inhibiting the retroviral Deoxyribonucleic acid (DNA) integration step. 3. How to use Ascriptega?Agriptera should be prescribed by a physician experienced in the treatment of HIV-1 infection. When using, patients need to swallow Agriptera tablets whole with a sufficient amount of water. Dosage of Agriptera: Adults and adolescents (from 12 years of age, weighing 40kg): The recommended dose is 1 Agriptera 50/300/300 tablet, once daily; Agriptera is not recommended for use in patients weighing less than 40 kg because Agriptera is formulated in a fixed-dose combination, so it is not possible to reduce the dose; Agriptera is a fixed-dose combination tablet and is therefore not suitable for HIV-infected patients requiring dose adjustment. The single-agent preparations of Lamivudine, Tenofovir disoproxil fumarate, and Dolutegravir are now available and are preferable in situations where discontinuation or dose adjustment of one of Agriptera's active ingredients is required.

Delivering to all over India Acriptega Tablet Written By Dr. Subita Alagh, BDS Reviewed By Dr. Sachin Gupta, MD Pharmacology, MBBS Last updated on 02 Feb 2026 | 07:41 PM (IST) Acriptega Tablet is a combination of antiretrovirals medicines. It is prescribed to treat HIV (human immunodeficiency virus) infection. It boosts up the immunity to fight against HIV to manage or treat AIDS (acquired immunodeficiency syndrome). Genuine Authenticity Assured Prescription required NPPA Regulated Show Details 3281 MRP 35909% off Acriptega Tablet is currently sold out Same composition alternative: Viropil Tablet 3278 3622.04 ADD Apply coupon to get EXTRA 15% OFF on medicines Available alternative from Top Brand Sold out Acriptega Tablet bottle of 30 tablets 3281 3590 Same composition ADD Viropil Tablet bottle of 30 tablets Dolutegravir (50mg) + Lamivudine (300mg) + Tenofovir disoproxil fumarate (300mg) by Emcure Pharmaceuticals Ltd Get in 60 mins 3278 92.87 per tablet 2786 order for 1200 Save more with additional offers Up to 500 cashback via RuPay Credit Card on UPI Up to 500 cashback via RuPay Credit Card on UPI 10% cashback up to 200 on Min Transaction of Rs.1000, for first time users of Airtel Payments Bank. 10% cashback up to 200 on Min Transaction of Rs.1000, for first time users of Airtel Payments Bank. Earn cashback up to Rs. 100 with Amazon Pay Later Earn cashback up to Rs. 100 with Amazon Pay Later See all offers General Information Contains Dolutegravir (50mg)+ Lamivudine (300mg)+ Tenofovir disoproxil fumarate (300mg) Marketer Mylan Pharmaceuticals Pvt Ltd Storage Store below 30C Product information Uses Benefits Side effects Usage How it works Substitutes Quick tips Safety advice Frequently asked questions The content is shown in English Product introduction Acriptega Tablet restricts the growth of HIV in the body and reduces the risk of getting HIV-related complications to improve the lifespan of an individual. The medicine can be taken with or without food. Taking these medicines regularly at the same time increases their effectiveness. A dose of this medicine should not be missed as it can affect